BARCELONA, Spain--(BUSINESS WIRE)--The international pharmaceutical company Ferrer has announced the extension of its phase III clinical trial ADORE (ALS trial with Daily ORal Edaravone), with FNP122 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results